Digitisation | August 05, 2021
Clarivate acquires Bioinfogate
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines
WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
The new greenfield manufacturing facility will be operated alongside the Guwahati facility as a parallel unit thereby helping mitigate the risks of a single-location operation
Winlevi has been approved by the United States FDA as a novel drug with a unique mechanism of action for the topical treatment of acne in patients 12 years and older
The company is confident of commencing production at both Mahad and Chiplun units soon
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
Subscribe To Our Newsletter & Stay Updated
